MA28093A1 - Forme polymorphe de 3-phenylsulfonyl-8-piperazine-1-yl-quinoleine - Google Patents

Forme polymorphe de 3-phenylsulfonyl-8-piperazine-1-yl-quinoleine

Info

Publication number
MA28093A1
MA28093A1 MA28933A MA28933A MA28093A1 MA 28093 A1 MA28093 A1 MA 28093A1 MA 28933 A MA28933 A MA 28933A MA 28933 A MA28933 A MA 28933A MA 28093 A1 MA28093 A1 MA 28093A1
Authority
MA
Morocco
Prior art keywords
phenylsulfonyl
quinoline
piperazine
polymorph form
disorders
Prior art date
Application number
MA28933A
Other languages
English (en)
Inventor
Asa Elisabeth Gladwin
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA28093A1 publication Critical patent/MA28093A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Forme polymorphe de 3-phénylsulfonyl-8 -pipérazine-1-yl- quinoléine Cette invention concerne un composé nouveau de 3- phénylsulfonyl-8-pipérazine-1-yl-quinoléine, des procédés pour sa préparation, des compositions le contenant et son utilisation dans le traitement de troubles du XX et d'autres troubles.
MA28933A 2003-09-26 2006-04-13 Forme polymorphe de 3-phenylsulfonyl-8-piperazine-1-yl-quinoleine MA28093A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0322629.7A GB0322629D0 (en) 2003-09-26 2003-09-26 Novel compound

Publications (1)

Publication Number Publication Date
MA28093A1 true MA28093A1 (fr) 2006-08-01

Family

ID=29286934

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28933A MA28093A1 (fr) 2003-09-26 2006-04-13 Forme polymorphe de 3-phenylsulfonyl-8-piperazine-1-yl-quinoleine

Country Status (23)

Country Link
US (1) US20070032504A1 (fr)
EP (1) EP1667975B1 (fr)
JP (1) JP2007506702A (fr)
CN (1) CN1856471A (fr)
AU (1) AU2004283805A1 (fr)
BR (1) BRPI0414678A (fr)
CA (1) CA2540022A1 (fr)
CO (1) CO5680402A2 (fr)
DE (1) DE602004010410T2 (fr)
DK (1) DK1667975T3 (fr)
ES (1) ES2297465T3 (fr)
GB (1) GB0322629D0 (fr)
HR (1) HRP20080055T3 (fr)
IL (1) IL174213A0 (fr)
IS (1) IS8399A (fr)
MA (1) MA28093A1 (fr)
MX (1) MXPA06003375A (fr)
NO (1) NO20061791L (fr)
PL (1) PL1667975T3 (fr)
PT (1) PT1667975E (fr)
RU (1) RU2355681C2 (fr)
WO (1) WO2005040124A1 (fr)
ZA (1) ZA200601453B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2386828T3 (es) * 2002-03-27 2012-08-31 Glaxo Group Limited Derivados de quinolina y su uso como ligandos 5-HT6
US8754238B2 (en) 2003-07-22 2014-06-17 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
PT1663958E (pt) 2003-09-18 2015-06-01 Virobay Inc Compostos contendo haloalquilo como inibidores de protease de cisteína
MX2007014929A (es) 2005-06-02 2008-02-15 Hoffmann La Roche 3-metansulfonilquinolinas como mejoradores de gaba-b.
GB0519758D0 (en) * 2005-09-28 2005-11-09 Glaxo Group Ltd Novel process
WO2008113818A1 (fr) * 2007-03-21 2008-09-25 Glaxo Group Limited Utilisation de composés pour le traitement de la douleur et du syndrome du côlon irritable
US9084742B2 (en) 2007-12-12 2015-07-21 Axovant Sciences Ltd. Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2010062321A1 (fr) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Procédés utiles pour la préparation de 1-[3-(4-bromo-2-méthyl-2h-pyrazol-3-yl)-4-méthoxy-phényl]-3-(2,4-difluoro‑phényl)-urée, et formes cristallines associées
RU2017145976A (ru) 2015-06-12 2019-07-15 Аксовант Сайенсиз Гмбх Производные диарил- и арилгетероарилмочевины, применимые для профилактики и лечения нарушения поведения во время REM-фазы сна
TW201720439A (zh) 2015-07-15 2017-06-16 Axovant Sciences Gmbh 用於預防及治療與神經退化性疾病相關的幻覺之作為５－ｈｔ２ａ血清素受體的二芳基及芳基雜芳基脲衍生物
WO2017202206A1 (fr) * 2016-05-27 2017-11-30 深圳市塔吉瑞生物医药有限公司 Composé quinoléine substitué et composition pharmaceutique correspondante

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9818916D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
ES2386828T3 (es) * 2002-03-27 2012-08-31 Glaxo Group Limited Derivados de quinolina y su uso como ligandos 5-HT6
GB0321473D0 (en) * 2003-09-12 2003-10-15 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
HRP20080055T3 (en) 2008-02-29
HK1094190A1 (en) 2007-03-23
DE602004010410D1 (en) 2008-01-10
DE602004010410T2 (de) 2008-10-16
ZA200601453B (en) 2007-04-25
IS8399A (is) 2006-04-05
NO20061791L (no) 2006-04-24
CO5680402A2 (es) 2006-09-29
RU2355681C2 (ru) 2009-05-20
EP1667975B1 (fr) 2007-11-28
PL1667975T3 (pl) 2008-04-30
CA2540022A1 (fr) 2005-05-06
ES2297465T3 (es) 2008-05-01
GB0322629D0 (en) 2003-10-29
CN1856471A (zh) 2006-11-01
MXPA06003375A (es) 2006-06-08
WO2005040124A1 (fr) 2005-05-06
DK1667975T3 (da) 2008-04-14
EP1667975A1 (fr) 2006-06-14
JP2007506702A (ja) 2007-03-22
BRPI0414678A (pt) 2006-11-28
AU2004283805A1 (en) 2005-05-06
PT1667975E (pt) 2008-02-29
RU2006114024A (ru) 2007-11-10
IL174213A0 (en) 2006-08-01
US20070032504A1 (en) 2007-02-08

Similar Documents

Publication Publication Date Title
TN2009000059A1 (fr) Formes de dosage pharmaceutiques orales anti-manipulation contenant un analgesique opioide
MA30999B1 (fr) Composés.
MA26697A1 (fr) Composes nouveaux inhibiteurs de gsk-3 et compositions pharmaceutiques les contenant
TNSN00121A1 (fr) Composes nouveaux inhibiteurs de metalloproteases, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN01145A1 (fr) Derives d'imidazole a noyau aryle ou heteroaryle condense, et compositions les contenant.
TNSN00092A1 (fr) Composes nouveaux antagonistes de npy, procede pour leur preparation et compositions pharmaceutiques les contenant
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
TNSN98084A1 (fr) Derives de macrolides substitues en position c-4
NO20050741L (no) Ny fremgangsmate for syntesen og ny krystallinsk form av agomelatin og farmasoytiske sammensetninger inneholdende den
TNSN99031A1 (fr) Composes heterocycliques nouveaux inhibiteurs de romatases, procede pour leur preparation et compositions pharmaceutiques les contenant
CA2407100A1 (fr) 1-aroyle-piperidinyle benzamidines
TNSN02009A1 (fr) Pyrimidinones bicycliques condensees nouvelles, inhibitrices de mmp, et compositions les contenant.
MA27774A1 (fr) Inhibiteurs de phosphatidylinositol 3-kinase
TN2009000138A1 (fr) Biaryl-ether-urees
TNSN99039A1 (fr) Bicyclo [2.2.1] heptanes nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99106A1 (fr) Derives d'isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA29692B1 (fr) Derives de la xanthine en tant qu'agonistes selectifs du hm74a
MXPA04004464A (es) Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades.
TNSN98238A1 (fr) Macrolides nouveaux
TNSN99172A1 (fr) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN07275A1 (fr) Derives de triazole substitues, servant d'antagonistes d'ocytocine
TNSN99156A1 (fr) Derives d'acide hydroxypipecolate-hydroxamique nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA30289B1 (fr) Dérivés d'amines
TNSN97198A1 (fr) Derives de 6-phenylpyridyl-2- amine et compositions pharmaceutiques les contenant